---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020615"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:08:14.616531+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024

## Summary
- Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).
- Cash, equivalents, and marketable securities $236.2M; cash runway into 2026.
- Phase 3 REACH trial for losmapimod in FSHD on track for topline data in Q4 2024 after enrolling 260 patients.
- Phase 1b PIONEER trial for pociredir in SCD restarted; cohorts evaluating 12 mg and 20 mg daily doses.

## SEC filing metadata
- accession: 0000950170-24-020615
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/0000950170-24-020615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/fulc-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020615
- JSON: https://secwatch.observer/filing/0000950170-24-020615.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020615.txt

## Key facts
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported fourth quarter and full year of 2023 results: revenue $0.9 million, net income $(24.8) million.
  - Period: fourth quarter and full year of 2023
  - Revenue: $0.9 million
  - Net income: $(24.8) million
  - Result: reported results
  source text: offering completed in January 2023 of $117.3 million, partially offset by our net cash used in operating activities in 2023. • Collaboration Revenue: Collaboration revenue was $0.9 million for the fourth quarter of 2023 as compared to $0.7 million for the fourth quarter of 2022. The increase of $0.2 million was attributable to an increase in revenues under our
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/0000950170-24-020615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.